Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.

Bone Marrow Transplant · 2016 · PMC4880046 · PMID 26901708

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0920

boldest claim

The sentences

highly significantP =0.0001actually significant

Importantly, a diagnosis of non-Hodgkin lymphoma (NHL) was associated with a highly significant reduction in the risk of EBV reactivation (HR 0.10, CI 0.03–0.33; P =0.0001).

also in 132,142 other papers

borderline significanceP =0.092so close (0.05 < p ≤ 0.1)

Furthermore, although the intensity of transplant conditioning was not significantly predictive overall, Flu Mel conditioning was associated with increased risk relative to Cy TBI (HR 0.63, CI 0.37–1.08; P =0.092, borderline significance).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.